CNS/Brain Cancer
Conference Coverage
CBSM phone app eases anxiety, depression in cancer patients
Few patients with cancer have access to psycho-oncologic support.
Conference Coverage
Huge underuse of germline testing for cancer patients
Information from germline genetic testing could affect a patient’s cancer care.
Conference Coverage
DEI training gives oncology fellows more confidence
Only 2%-3% of practicing oncologists are Black or Hispanic/Latino, says Yale Cancer Center doctor.
Feature
Drugmakers are abandoning cheap generics, and now U.S. cancer patients can’t get meds
On Nov. 22, three FDA inspectors arrived at the sprawling Intas Pharmaceuticals plant south of Ahmedabad, India, and found hundreds of trash bags...
Conference Coverage
ACS officer provides ASCO highlights: Targeting hidden cancer, AI in oncology
A pair of new studies show that drugs can reduce cancer risk when cells are elusive.
Feature
Widespread carboplatin, cisplatin shortages: NCCN survey
Only 64% of centers said they are still able to continue treating all current patients receiving carboplatin.
Conference Coverage
Oral drug for brain tumor could change treatment landscape
Vorasidenib was associated with a significant delay in time to disease progression when compared with placebo, in a new study.
From the Journals
Number of cancer survivors with functional limitations doubled in 20 years
The 70% prevalence of functional limitation among survivors in 2018 is nearly twice that of the general population.
From the Journals
Study shows higher obesity-related cancer mortality in areas with more fast food
An ecologic study showed a dose-response relationship among measures of food swamp and food desert scores and obesity-related cancer mortality.
Conference Coverage
Expert discusses which diets are best, based on the evidence
The Mediterranean diet is not only helpful for losing weight but also can reduce the risk of various chronic diseases.
From the Journals
Plasma monitoring supports earlier osimertinib treatment in lung cancer patients
More patients met progression-free survival endpoints after shorter stint on gefitinib.